<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112635">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01914666</url>
  </required_header>
  <id_info>
    <org_study_id>14949</org_study_id>
    <secondary_id>F1J-JE-HMHC</secondary_id>
    <nct_id>NCT01914666</nct_id>
  </id_info>
  <brief_title>An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain</brief_title>
  <official_title>Phase 3 Clinical Study of Duloxetine Hydrochloride in Patients With CLBP - Open Label Long Term Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shionogi and Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the long term safety of duloxetine in participants
      with Chronic Low Back Pain (CLBP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Drug Related Adverse Events (AEs) or any Serious AE's</measure>
    <time_frame>Week 53</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Brief Pain Inventory (BPI) Pain Severity Item and Interference Item to Week 50</measure>
    <time_frame>Baseline, Week 50</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-Improvement) to Week 50</measure>
    <time_frame>Week 50</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impression of Severity (CGI-Severity) to Week 50</measure>
    <time_frame>Baseline, Week 50</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Roland Morris Disability Questionnaire (RMDQ-24) to Week 50</measure>
    <time_frame>Baseline, Week 50</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 36-Item Short-Form Health Survey (SF-36) to Week 50</measure>
    <time_frame>Baseline, Week 50</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Quality of Life Questionnaire-5 Dimension (EQ-5D) to Week 50</measure>
    <time_frame>Baseline, Week 50</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Beck Depression Inventory-II (BDI-II) to Week 50</measure>
    <time_frame>Baseline, Week 50</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) to Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Fall Events from Fall Questionnaire</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Back Pain Lower Back Chronic</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. Tapering week doses of 40 mg for first week and 20 mg for second week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
    <other_name>LY248686</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (Consecutive Participants):

          -  Participants who have completed the 15-week administration in the phase 3 clinical
             study of Duloxetine hydrochloride in participants with CLBP, study HMGY (NCT01855919)

          -  Female participants having child-bearing potential must test negative (-) on a
             pregnancy test

        (New Participants):

          -  Participants with CLBP present for the preceding 6 months or longer

          -  Participants used nonsteroidal anti-inflammatory drugs for CLBP for less than 14 days
             on average per month in the past 3 months and less than 14 days in one month prior to
             study

          -  Participants having a score of â‰¥4 on Brief Pain Inventory (BPI) average pain score at
             participation of study

          -  Female participants having child-bearing potential must test negative (-) on a
             pregnancy test

        Exclusion Criteria:

        (Consecutive Participants):

          -  Participants having serious or unstable cardiovascular, hepatic, renal, metabolic,
             respiratory, or hematologic illness, symptomatic peripheral vascular disease, or
             other medical condition or psychiatric conditions that, in the opinion of
             investigator, would compromise participation or be likely to lead to hospitalization
             during the course of the study

          -  Participants having alanine aminotransferase or aspartate aminotransferase higher
             than 100 International Units per Liter (IU/L) or total bilirubin higher than 1.6
             milligram per deciliter (mg/dL)

          -  Participants having serum creatinine level higher than 2.0 mg/dL, or had renal
             transplantation or receiving renal dialysis

          -  Participants having diagnosis seronegative spondyloarthropathy or rheumatoid
             arthritis

          -  Participants having primary painful condition due to other than CLBP

          -  Participants having uncorrected thyroid disease, uncontrolled narrow-angle glaucoma,
             history of uncontrolled seizures, or uncontrolled or poorly controlled hypertension

          -  Participants treating with a monoamine oxidase inhibitor (MAOI) within 14 days or the
             potential need to use an MAOI during the study or within 5 days of discontinuation of
             study drug

          -  Participants answering &quot;yes&quot; to any of the questions about active suicidal
             ideation/intent/behaviors occurring within the past month (Columbia Suicide Severity
             Rating Scale, Suicide Ideation section - Questions 4 and 5; Suicidal Behavior
             section)

          -  Pregnant participants or participants who are breast-feeding, or wished to be
             pregnant during the clinical trial period

          -  Participants cannot use appropriate contraceptive method or do not want to use that
             from participation of study until one month after the end of administration of the
             investigational drug

          -  Participants being considered as inappropriate for participation to the study for any
             medical or other reason as judged by the investigator

        (New Participants):

          -  Participants having serious or unstable cardiovascular, hepatic, renal, metabolic,
             respiratory, or hematologic illness, symptomatic peripheral vascular disease, or
             other medical condition or psychiatric conditions that, in the opinion of
             investigator, would compromise participation or be likely to lead to hospitalization
             during the course of the study

          -  Participants having alanine aminotransferase or aspartate aminotransferase higher
             than 100 IU/L or total bilirubin higher than 1.6 mg/dL

          -  Participants having serum creatinine level higher than 2.0 mg/dL, or had renal
             transplantation or receiving renal dialysis

          -  Participants having diagnosis seronegative spondyloarthropathy or rheumatoid
             arthritis

          -  Participants having primary painful condition due to other than CLBP

          -  Participants having a history of low back surgery

          -  Participants having any previous diagnosis of psychosis, bipolar disorder, or
             schizoaffective disorder

          -  Participants having major depressive disorder as determined using depression module
             of the Mini-International Neuropsychiatric Interview

          -  Participants having uncorrected thyroid disease, uncontrolled narrow-angle glaucoma,
             history of uncontrolled seizures, or uncontrolled or poorly controlled hypertension

          -  Participants treating with a MAOI within 14 days or the potential need to use an MAOI
             during the study or within 5 days of discontinuation of study drug

          -  Participants answering &quot;yes&quot; to any of the questions about active suicidal
             ideation/intent/behaviors occurring within the past month (Columbia Suicide Severity
             Rating Scale, Suicide Ideation section - Questions 4 and 5; Suicidal Behavior
             section)

          -  Participants have known hypersensitivity to multiple medications

          -  Participants are non-ambulatory or require the use of crutches or a walker

          -  Participants having a history of substance abuse or dependence within the past year,
             excluding nicotine and caffeine

          -  Participants having a positive urine drug screen for any substances of abuse

          -  Participants have received treatment within the last 30 days with a drug that has not
             received regulatory approval for any indication

          -  Participants have had previous exposure to duloxetine or completed / withdrawn from
             any study investigating duloxetine

          -  Pregnant participants or participants who are breast-feeding, or wished to be
             pregnant during the clinical trial period

          -  Participants cannot use appropriate contraceptive method or do not want to use that
             from participation of study until one month after the end of administration of the
             investigational drug

          -  Participants being considered as inappropriate for participation to the study for any
             medical or other reason as judged by the investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY  (1-877-285-4559 ) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>330-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 11, 2013</lastchanged_date>
  <firstreceived_date>July 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Low Back Pain</keyword>
  <keyword>CLBP</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Duloxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
